Historical shareholding details of iShares Biotechnology ETF holdings in Enliven Therapeutics Inc (ELVN)

Monthly changes of iShares Biotechnology ETF shareholding in Enliven Therapeutics Inc over the previous months

Month Name Total no. shares held Percent Holding
Mar 28, 2025 Ishares Biotechnology Etf 203,924 0.42%
Mar 25, 2025 Ishares Biotechnology Etf 205,274 0.42%
Feb 28, 2025 Ishares Biotechnology Etf 179,822 0.37%
Feb 26, 2025 Ishares Biotechnology Etf 187,094 0.38%
Jan 31, 2025 Ishares Biotechnology Etf 190,932 0.39%
Jan 29, 2025 Ishares Biotechnology Etf 191,336 0.39%
Jan 28, 2025 Ishares Biotechnology Etf 190,326 0.39%
Dec 31, 2024 Ishares Biotechnology Etf 196,588 0.40%
Dec 30, 2024 Ishares Biotechnology Etf 198,002 0.41%
Dec 27, 2024 Ishares Biotechnology Etf 197,194 0.40%
Nov 30, 2024 Ishares Biotechnology Etf 197,396 0.40%
Nov 27, 2024 Ishares Biotechnology Etf 199,214 0.41%
Oct 31, 2024 Ishares Biotechnology Etf 203,254 0.43%
Oct 30, 2024 Ishares Biotechnology Etf 204,466 0.43%
Oct 29, 2024 Ishares Biotechnology Etf 204,466 0.43%
Sep 30, 2024 Ishares Biotechnology Etf 210,728 0.45%
Sep 27, 2024 Ishares Biotechnology Etf 210,324 0.45%
Sep 25, 2024 Ishares Biotechnology Etf 211,940 0.45%
Aug 30, 2024 Ishares Biotechnology Etf 196,267 0.42%
Aug 29, 2024 Ishares Biotechnology Etf 196,267 0.42%
Aug 28, 2024 Ishares Biotechnology Etf 194,787 0.41%
Jul 31, 2024 Ishares Biotechnology Etf 198,302 0.42%
Jul 26, 2024 Ishares Biotechnology Etf 198,302 0.42%
Jun 28, 2024 Ishares Biotechnology Etf 199,042 0.42%
Jun 13, 2024 Ishares Biotechnology Etf 197,086 0.42%
May 30, 2024 Ishares Biotechnology Etf 150,541 0.32%
May 29, 2024 Ishares Biotechnology Etf 151,109 0.32%
Apr 26, 2024 Ishares Biotechnology Etf 157,215 0.33%
Mar 28, 2024 - - 0.34%
Mar 27, 2024 Ishares Biotechnology Etf 162,318 0.39%
Feb 29, 2024 Ishares Biotechnology Etf 148,949 0.36%
Feb 28, 2024 Ishares Biotechnology Etf 149,619 0.36%
Jan 29, 2024 Ishares Biotechnology Etf 147,877 0.36%
Dec 27, 2023 Ishares Biotechnology Etf 146,537 0.36%

View all ownership details of Enliven Therapeutics Inc